The Forum for Collaborative HIV Research - Forum HCV Drug Resistance Slideset (ResisSS 2012 V.2)

Announcements

On Behalf of IDSA: Urge Lawmakers to Protect PEPFAR Funding

MAY-22-13 IDSA is asking for you to join them and lend your name to a letter in support of PEPFAR funding for the next fiscal year. Click here to read the letter and sign by Monday, June 3-Noon Eastern time.

Renewal of the National Viral Hepatitis Action Plan, 2014-2016

MAY-20-13 Dr. Ronald Valdiserri writes to recognize the second anniversary of Combating the Silent Epidemic of Viral Hepatitis: Action Plan for the Prevention, Care & Treatment of Viral Hepatitis and to share an important announcement from Dr. Howard Koh about plans to update and renew the existing plan through 2014-2016.

HIV Forum congrulates Nina Mani on her new position at FDA

MAY-17-13 Please join the Forum in congratulating Nina Mani on an exciting new career move. Nina is leaving the Forum, but she is not going far – starting June 3 she will join the FDA Center for Drug Evaluation Research, Division of Antiviral Products. That we will miss her is the understatement of the century. But the offer to join our colleagues at the FDA as a project manager presented a phenomenal opportunity – an excellent fit for her career path. We congratulate Jeff, Kim, Jules and Patrick on an excellent choice! We imagine that many of you will have the pleasure of interacting with her in her new capacity.

National Viral Hepatitis Action Plan to Be Renewed

MAY-16-13 Dr. Howard Koh, the Assistant Secretary for Health, announced on May 16 that the partner agencies are committed and dedicated to renewing the Action Plan for another three years and are currently working on their vision and priorities for 2014-2016.

HIV Forum Mourns the Passing of Executive Committee Member Dr. Jim Goodrich

MAY-10-13 We are saddened to report the death of James Goodrich, PhD, MD of ViiV Healthcare, a member of the Forum’s Executive Committee. Jim passed away unexpectedly last weekend and is survived by his wife, Carolyn and two teenage daughters. A memorial service for Jim will be held this summer on a date to be determined. Jim has been a considered and thoughtful participant on the Executive Committee. His desire to improve care for patients, direct approach and sense of humor will be missed. Please join us in keeping Jim’s family in our thoughts and prayers.

Upcoming Events

29-Jun-13

IAS 2013 Towards an HIV Cure Symposium

14-Jun-13

FDA Public Meeting on HIV Patient-Focused Drug Development and HIV Cure Research

04-Jun-13

International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies

23-May-13

Hepatitis B and C Testing and Awareness Day in House of Representatives

Forum HCV Drug Resistance Slideset (ResisSS 2012 V.2)

User Comments

"These HCV slides are wonderful. Thanks to the Forum for making them available for educational purposes."
-W. David Hardy, MD, Cedars-Sinai Medical Center & David Geffen School of Medicine at UCLA

"Great work! Good slide sets."
- Donald M. Jensen, MD, University of Chicago Medicine

Click here to share your comments

Given the rapid pace of HCV drug development, the Forum's ResisSS has been updated and revised into four subsets:

1. HCV Lifecycle, Drug Targets, and Mechanisms of Action | PPT | PDF |
2. HCV Resistance Barriers, Selection and Monitoring of Resistance | PPT | PDF |
3. HCV Treatment Strategies to Reduce Drug Resistance | PPT | PDF |
4. HCV Patient and Regimen Factors that Maximize Response and Minimize Resistance | PPT | PDF |

Along with incorporating recent data from AASLD 2012, the #3 Treatment Strategies set has been subdivided into interferon-containing and interferon-free regimens.

Recognizing the need for HCV drug resistance education, the members of the Forum for Collaborative HIV Research's HCV Drug Development Advisory Group (academicians, clinicians, researchers and patient advocates) have contributed to a slide deck explaining drug resistance in HCV, its consequences, as well as mitigating its impact.

The educational slide deck’s intended audience ranges the spectrum from health care providers evaluating, diagnosing and treating HCV, patients who want to learn about the disease and treatment options, and advocates who may use the slides in their community education outreach efforts.

These slides may be used in the user's own noncommercial presentations, but kindly do not change content and attribution. We also ask that the slides not be published or posted online without permission from the Forum for Collaborative HIV Research.

For comments or more information, please contact Erik Lontok (elontok@hivforum.org)